This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmAthene Progresses Second Generation RPA Anthrax Vaccine

ANNAPOLIS, Md., Oct. 31, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax™.  The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency.  The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale.  Final analytical testing is ongoing and expected to be completed in December.

"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency.  A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields," remarked Eric I. Richman, President and Chief Executive Officer. "SparVax™ is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health (NIH) to advanced development in partnership with the Biomedical Advanced Research and Development Authority (BARDA).  SparVax™ represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country.  We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."

"This achievement marks the latest in a series of accomplishments for our rPA anthrax vaccine program in 2011," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer. "Earlier this year, we successfully completed the technology transfer of our manufacturing process from the United Kingdom to a United States-based contract manufacturing organization.  Most importantly, PharmAthene has data supporting 36 months of stability for SparVax™ – an important accomplishment given the historical issues associated with rPA anthrax vaccine stability.  The use of recombinant vaccine technology employing modern, industrial biotechnology manufacturing processes provides the flexibility to produce a well-characterized product that can be rapidly scaled-up for production in the event of a national emergency.  

A key differentiator for PharmAthene's rPA technology platform is the utilization of E. coli.  This technology enables a more robust manufacturing process and the capability of annually producing more than 150 million rPA vaccine equivalent doses of bulk drug substance (at a 50 mcg dose) – a substantial improvement in  rPA production yield without the production of destructive proteases. In addition, PharmAthene's manufacturing platform has the ability to produce stable production intermediates in the event surge capacity is required.  All these factors contribute to key advantages of SparVax™ over other rPA-based anthrax vaccine programs."

PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs